The COVID-19 monoclonal antibody therapy Evusheld may not prevent COVID-19 caused by certain variants of the virus, the Food and Drug Administration announced this week. For details, see the updated fact sheet for health care providers
 
FDA last year authorized the combination monoclonal antibody therapy for emergency use to help prevent COVID-19 in certain adults and children with compromised immune systems or a history of severe adverse reaction to a COVID-19 vaccine or its components. FDA continues to recommend Evusheld to prevent COVID-19 as it still offers protection against many circulating variants, but encourages patients to be prepared to test and seek immediate treatment if they experience COVID-19 symptoms. The agency also continues to recommend that people who can get vaccinated and boosted to prevent COVID-19.
 

Related News Articles

Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
The Home Test to Treat program now offers free testing, telehealth and treatment for both COVID-19 and flu to eligible adults nationwide, the National…
Headline
The Food and Drug Administration Nov. 9 cleared for marketing the Flowflex COVID-19 Antigen Home Test, the first COVID-19 antigen test and second COVID-19 at-…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…